2021 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study | Kelley, Robin Kate; Sangro, Bruno; Harris, William; Ikeda, Masafumi; Okusaka, Takuji; Kang, Yoon-Koo; Qin, Shukui; Tai, David W-M; Lim, Ho Yeong; Yau, Thomas; Yong, Wei-Peng; ANN-LII CHENG ; Gasbarrini, Antonio; Damian, Silvia; Bruix, Jordi; Borad, Mitesh; Bendell, Johanna; Kim, Tae-You; Standifer, Nathan; He, Philip; Makowsky, Mallory; Negro, Alejandra; Kudo, Masatoshi; Abou-Alfa, Ghassan K | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 237 | 215 | |
2022 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | ANN-LII CHENG ; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R; Ducreux, Michel; Kim, Tae-You; Lim, Ho Yeong; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; Zhu, Andrew X; Finn, Richard S | Journal of hepatology | 490 | 463 | |